Sponsor:
University of Utah
Code:
NCT07216248
Conditions
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Eligibility Criteria
Sex: Male
Age: 18+
Healthy Volunteers: Not accepted
Interventions
relugolix + ARPI
Intermittent- Relugolix or androgen deprivation therapy (ADT) + ARPI
relugolix or androgen deprivation therapy (ADT) + ARPI
relugolix + ARPI.
Study Details
Eligibility Criteria
Study Design
Interventions and Outcome Measures
Central Contacts and Locations
More Information
Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-05. This information was provided to ClinicalTrials.gov by University of Utah on 2025-10-29.